However, except for HSD11B1 and SH2D2A in infiltrating ductal carcinoma, other MDGs did not have statistically significant clinical outcome (Figure S2F-G), possibly due to small sample size. This evidence concerns the gene SH2D2A and invasive ductal breast carcinoma.